Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 05TAIPEI4764, TAIWAN ISSUES TAMIFLU COMPULSORY LICENSE, BUT DOES

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #05TAIPEI4764.
Reference ID Created Released Classification Origin
05TAIPEI4764 2005-11-30 22:55 2011-08-23 00:00 UNCLASSIFIED American Institute Taiwan, Taipei
This record is a partial extract of the original cable. The full text of the original cable is not available.

302255Z Nov 05
UNCLAS SECTION 01 OF 02 TAIPEI 004764 
 
SIPDIS 
 
STATE FOR EAP/RSP/TC ADN EB/TPP/MTA/IPC, STATE PASS AIT/W 
AND USTR, USTR FOR WINTERS AND WINELAND, USDOC FOR 
4431/ITA/MAX/AP/OPB/TAIWAN/MBMORGAN 
 
E.O. 12958: N/A 
TAGS: ETRD ECON KIPR TW ESTH IPR
SUBJECT: TAIWAN ISSUES TAMIFLU COMPULSORY LICENSE, BUT DOES 
IT MATTER? 
 
 
1.  Summary: Taiwan Intellectual Property Office (TIPO) 
Deputy Director General Jack Lu announced late November 25 
that Taiwan would grant the Taiwan Department of Health (DOH) 
a restricted license to produce Tamiflu, despite the fact 
that negotiations between DOH and patent-holder Roche were 
on-going.  The Taiwan government justified its decision to 
issue the compulsory license by claiming Roche was unable to 
provided Taiwan with sufficient doses of the Avian Influenza 
(AI) treatment to meet World Health Organization (WHO) 
recommended guidelines.  The license requires DOH to first 
exhaust Roche-produced stock of Tamiflu before distributing 
locally manufactured medicine and prohibits the export of 
product manufactured under the license.  Roche's spokesperson 
insisted the company could meet Taiwan demand and charged 
that Taiwan's drug manufacturers did not have the 
technological capability to produce the drug.  End Summary. 
 
2.  Following several months of negotiations between Taiwan's 
DOH and Swiss drug-manufacturer Roche over supply of AI 
treatment Tamiflu, discussions which included the licensing 
of local production, TIPO announced November 25 that it would 
license DOH to produce a copy of the drug.  However, TIPO's 
announcement stipulated that locally produced versions would 
be solely for domestic use and would be used only in the 
event that supplies of Roche-produced Tamiflu were exhausted. 
 Roche's spokesperson countered in the press that Taiwan 
lacked the technical capability to produce Tamiflu.  She 
insisted that Roche would be able to provide Taiwan with the 
necessary supply. 
 
=============================== 
Taiwan Seeking Self-sufficiency 
=============================== 
 
3.  According to TIPO's Director of International Affairs 
Bennet Chen, Taiwan currently has only enough Tamiflu in 
stock to treat less than 1% of the population, well below the 
WHO recommended stockpile of 10% of the population (2.3 
million doses for Taiwan.)  It was only after several months 
of negotiations with Roche that DOH on October 313 applied to 
TIPO for a compulsory license of Roche's patent, he said. 
After much discussion within TIPO, it was decide to grant a 
conditional license valid until December 2007 or until a 
licensing agreement is concluded between Taiwan and Roche. 
 
4.  DOH Bureau of Pharmaceutical Affairs Director General 
Liao Chi-chow told AIT that Roche had promised to provide 
Taiwan with 2.3 million doses of Tamiflu by June 2006, but 
that Taiwan health officials were concerned that the most 
dangerous period for AI infections was likely to be between 
January and March of 2006.  Roche had been adamantly opposed 
to licensing Tamiflu production to a Taiwan manufacturer, 
Liao said.  Given the global demand for Tamiflu, he doubted 
that Roche would be able to meet its commitment and dismissed 
Roche's pledge as empty talk. 
 
5.  Liao insisted that Taiwan has four or five manufacturers 
that are technically capable of producing Tamiflu.  He 
predicted that DOH would conduct an open tender for Tamiflu 
production in January.  Liao was uncertain when locally 
manufactured product might be available for the Taiwan 
market.  When asked how DOH planned to ensure that the local 
production of the drug did not leak onto the market or out of 
Taiwan, he responded that the Taiwan Center for Disease 
Control (Taiwan CDC) would maintain the stockpile in their 
warehouse and would be responsible for the security of the 
product. 
 
============================= 
TIPO Tries to Divide the Baby 
============================= 
 
6.  TIPO DDG Lu noted that Taiwan's decision was fully in 
compliance with Article 31 of the TRIPS Agreement and that 
use of locally produced Tamiflu would be strictly limited and 
controlled by DOH.  Lu suggested that TIPO had done its best 
to respect Roche's patent rights by requiring DOH to first 
deplete its stock of Tamiflu before turning to locally 
produced drugs and by prohibiting the export of any drugs 
produced under the compulsory license.  Negotiations between 
Roche and DOH over compensation and continued purchases of 
Tamiflu were continuing, he said.  Given the potential human 
cost of an AI pandemic, TIPO decided it was better to issue 
the license to DOH for local manufacture and restrict the 
usage of the resulting product.  This was their attempt at a 
compromise solution, offered Lu.  That the announcement came 
just days before important local elections, he claimed, was 
purely coincidental. 
 
============================= 
Comment: A Perplexing Outcome 
============================= 
 
7.  Roche announced November 26 that the Indonesian 
government was free to produce Tamiflu without a license and 
followed with similar announcements November 28 regarding 
Thailand and the Philippines.  In these countries, Roche had 
reportedly not filed a patent and therefore claimed not to 
have any patent protection.  However, Roche's willingness to 
cede the field in these countries, all potentially larger 
markets than Taiwan, makes the inability of the two sides to 
come to an agreement in Taiwan puzzling.  TIPO has 
spearheaded a drive to improve intellectual property rights 
protection in Taiwan over the past several years, but has 
also shown a willingness to use TRIPS Article 31 to allow the 
use of patents without the authorization of the rightsholder 
in certain instances.  Taiwan issued a compulsory license for 
patents to produce CD-Rs in July 2004 after years of 
negotiations between patent holder Philips and local optical 
disk manufacturers over royalty payments broke down, but 
resisted doing so when Taiwan peer-to-peer file sharing 
service Kuro claimed it was unable to reach a negotiated 
royalty plan with the International Federation of 
Phonographic Industries (IFPI). 
 
8.  Equally perplexing is how Taiwan plans to provide locally 
produced Tamiflu in time to make a difference.  DOH 
identifies the greatest period of risk as January to March 
2006 and plans to open a tender in January 2006.  Any company 
winning a tender will then need to develop a production 
capacity, acquire the raw materials, and train staff.  It is 
hard to imagine that regular production will begin in time to 
make any significant quantity of the drug available by March. 
Paal